Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
A tiny Michigan town's century
The real cost of your night out: From a £4.60 Diet Coke to £8.80
Moment twins, 8, hilariously fume after discovering two ice creams will cost them a staggering £9
The Starmer Stone! Keir apes Blair
Israel addressed Biden’s concerns over widescale Rafah operation: US official
Two boys, 12, stabbed teenager, 19, to death in park machete attack after victim 'shoulder
Inside the new show that gets couples who found love online to meet for the first time
Taiwan is selling more to the US than China in major shift away from Beijing
Russian general who criticized equipment shortages in Ukraine is arrested on bribery charges
Yemen's Houthi rebels claim shooting down another US MQ
Divided Supreme Court rules no quick hearing required when police seize property
Vermont to grant professional licenses, regardless of immigration status, to ease labor shortage